Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101
NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Columbia …